Newsroom

Featured Press Releases

June 18, 2013
ORAL ANTI-CANCER THERAPY REVLIMID® (LENALIDOMIDE) NOW INDICATED AS A TREATMENT FOR PATIENTS WITH RARE FORM OF BLOOD DISEASE
BOUDRY, SWITZERLAND – (June 15, 2013) – Celgene International Sàrl (NASDAQ: CELG) was today notified that the European Commission (EC) has amended the marketing authorisation for REVLIMID^®.
June 13, 2013
Data from Phase III Randomized Controlled Study (PALACE 3) of Apremilast in Psoriatic Arthritis Presented at EULAR
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company’s third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain...
June 12, 2013
Celgene Announces Additional $3.0 Billion Share Repurchase Program
Celgene Corporation (NASDAQ: CELG) announced today that its Board of Directors authorized the repurchase of up to an additional $3.0 billion of the Company’s common stock. Purchases may be made in the open market or in privately negotiated transactions from time to time, as...
June 12, 2013
Signs and Symptoms of Psoriatic Arthritis Significantly Improved in Patients Receiving Long-Term Oral Apremilast Treatment in Phase III Study (PALACE-1)
ABSTRACT #LB0001

3/4/13 8:51 pm EST
New Drugs Slow a Fast-Spreading Cancer
Two new drugs for multiple myeloma, approved in recent months, promise to extend life expectancy for patients with the blood cancer.
more...
2/18/13
Targeted Cancer Drugs Keep Myeloma Patients Up and Running
2/11/13 3:31 pm EST
Celgene Wins Chinese Approval for Revlimid